The industry continues to witness a series of triumphs in biomarker-driven therapies and companion diagnostics (CDx). With 157 FDA-approved CDx devices to date and recent collaborations between key biopharma and diagnostic providers such as Bristol Myers Squibb and Foundation Medicine, AstraZeneca, Grail, Servier, and Qiagen, the race to develop more sensitive and more reproductive diagnostics has become even fiercer in 2023.

Across 2 days, 80+ world-class industry stakeholders will address the most critical challenges in Biomarker Discovery & Translational Development, Clinical Biomarker Development, and CDx Development & Commercialization, to provide you with unparalleled insights to:

• Recognizing biomarkers & CDx development advancements in multiple disease areas spanning oncology and non-oncology indications including NASH, Alzheimer’s & Parkinson's to revolutionize personalized medicine efforts
• Exploring the regulatory, commercialization, and market access landscapes to take actional measures for the wider adoption and commercialization of testing and enable equitable access for patients
• Overcoming the challenges of analytically validating clinical biomarkers to ensure clinical trial robustness
• Utilize bioinformatics and AI for biomarker discovery, patient stratification, and clinical biomarker validation to enhance underlying biology and pathology understanding for biomarkers
• Collaborate with the hottest CDx developers to supercharge the co-development of therapeutics and companion diagnostics